These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 3064089)

  • 1. Lymphokine activated killer cells research in China.
    Ba DN
    Proc Chin Acad Med Sci Peking Union Med Coll; 1988; 3(3):170-4. PubMed ID: 3064089
    [No Abstract]   [Full Text] [Related]  

  • 2. Adoptive immunotherapy of cancer using lymphokine activated killer cells and recombinant interleukin-2.
    Rosenberg SA
    Important Adv Oncol; 1986; ():55-91. PubMed ID: 3330541
    [No Abstract]   [Full Text] [Related]  

  • 3. [Treatment of malignant tumors by interleukin 2 and LAK cells].
    Degos L
    Nouv Rev Fr Hematol (1978); 1988; 30(1-2):119-22. PubMed ID: 3260373
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhancement of human lymphokine-activated killer cell cytolysis and a method for increasing lymphokine-activated killer cell yields to cancer patients.
    Yannelli JR; Thurman GB; Mrowca-Bastin A; Pennington CS; West WH; Oldham RK
    Cancer Res; 1988 Oct; 48(20):5696-700. PubMed ID: 3262411
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lymphokine-activated killer cells: a new approach to immunotherapy of cancer.
    Rosenberg S
    J Natl Cancer Inst; 1985 Oct; 75(4):595-603. PubMed ID: 3876465
    [No Abstract]   [Full Text] [Related]  

  • 6. Adoptive immunotherapy of malignant diseases with IL-2-activated lymphocytes.
    Kimoto Y; Taguchi T
    Biken J; 1987 Jun; 30(2):29-38. PubMed ID: 3501954
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lymphokine-activated killer cells: in vitro and in vivo studies.
    Mazumder A
    Lymphokine Res; 1985; 4(3):215-20. PubMed ID: 3897730
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Adoptive immunotherapy: a new therapeutic approach to cancer based on interleukin 2].
    Sculier JP; Bron D; Delforge A; Stryckmans P; Klastersky J
    Rev Med Brux; 1987 Mar; 8(3):133-9. PubMed ID: 3495843
    [No Abstract]   [Full Text] [Related]  

  • 9. A new approach to generating antitumor effectors for adoptive immunotherapy using human adherent lymphokine-activated killer cells.
    Melder RJ; Whiteside TL; Vujanovic NL; Hiserodt JC; Herberman RB
    Cancer Res; 1988 Jun; 48(12):3461-9. PubMed ID: 3259468
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of cancer with lymphokine-activated killer cells and interleukin-2.
    N Engl J Med; 1987 Oct; 317(15):961-3. PubMed ID: 3498120
    [No Abstract]   [Full Text] [Related]  

  • 11. Interleukin-2 and lymphokine-activated killer cell therapy for gastrointestinal cancer.
    Guillou P
    Acta Chir Scand Suppl; 1989; 549():26-30. PubMed ID: 2784604
    [No Abstract]   [Full Text] [Related]  

  • 12. Successful immunotherapy of murine experimental hepatic metastases with lymphokine-activated killer cells and recombinant interleukin 2.
    Lafreniere R; Rosenberg SA
    Cancer Res; 1985 Aug; 45(8):3735-41. PubMed ID: 3893689
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adoptive immunotherapy of human cancer using low-dose recombinant interleukin 2 and lymphokine-activated killer cells.
    Schoof DD; Gramolini BA; Davidson DL; Massaro AF; Wilson RE; Eberlein TJ
    Cancer Res; 1988 Sep; 48(17):5007-10. PubMed ID: 3261630
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction of lymphokine-activated killer cells in strain 2 guinea pigs with human interleukin-2.
    Zwilling BS; Aldrich WA; Rinehart JJ
    Cancer Res; 1986 Nov; 46(11):5667-70. PubMed ID: 3489527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Augmentation of interleukin-2 immunotherapeutic effects by lymphokine-activated killer cells and allogeneic stimulation in murine tumor cells.
    Eggermont AM; Steller EP; Ottow RT; Matthews W; Sugarbaker PH
    J Natl Cancer Inst; 1987 Nov; 79(5):983-90. PubMed ID: 3500357
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Laboratory correlates of adoptive immunotherapy with recombinant interleukin-2 and lymphokine-activated killer cells in humans.
    Boldt DH; Mills BJ; Gemlo BT; Holden H; Mier J; Paietta E; McMannis JD; Escobedo LV; Sniecinski I; Rayner AA
    Cancer Res; 1988 Aug; 48(15):4409-16. PubMed ID: 3260537
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protective effect(s) of rIL-2 modulation. I. The effects of chemotherapeutic/cytotoxic agents on human natural killer cells and lymphokine-activated killer cells.
    Ades EW; Hinson A
    J Immunopharmacol; 1986; 8(4):481-97. PubMed ID: 3492564
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Use of interleukin 2-activated lymphocytes (LAK cells) in adoptive immunotherapy of neoplasms].
    Robak T
    Pol Tyg Lek; 1988 Nov; 43(47):1491-5. PubMed ID: 3266975
    [No Abstract]   [Full Text] [Related]  

  • 19. Circulating cytokines in patients with metastatic cancer treated with recombinant interleukin 2 and lymphokine-activated killer cells.
    Gemlo BT; Palladino MA; Jaffe HS; Espevik TP; Rayner AA
    Cancer Res; 1988 Oct; 48(20):5864-7. PubMed ID: 3139285
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Local regional promotion of tumor growth after abdominal surgery is dominant over immunotherapy with interleukin-2 and lymphokine activated killer cells.
    Eggermont AM; Steller EP; Marquet RL; Jeekel J; Sugarbaker PH
    Cancer Detect Prev; 1988; 12(1-6):421-9. PubMed ID: 3263198
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.